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Background: In clinical trials of revascularization the terms “coronary artery disease” and “ischemic heart disease” are sometimes used 
interchangeably. This can create confusion in inclusion and exclusion criteria, which may lead to uncertain results. Our purpose is to investigate 
if the clinical trials population comparing percutaneous coronary revascularization to medical therapy for stable ischemic heart disease reflects 
specifically concerns patients with demonstrable ischemia and how many patients are included in the trial with the only evidence of coronary 
atherosclerosis and without ischemia. 
Methods: Individual trials data (number of patients screened, number of patients enrolled, number of patients with positive stress test or without 
stress test) were obtained from ACME I, ACME II, RITA I, RITA II, MASS I, MASS II, AVERT, ACIP and COURAGE. Published data were used to calculate the 
number of patients included in the trials with negative stress test but significant coronary artery stenosis and the number of patients excluded from 
the trials with positive stress test or angina (but without significant coronary artery stenosis at the time of angiography). 
Results: More then 195.213 people have been screened from 1998 to 2011. Overall about 30% of patients were excluded if they did not met 
the angiographic criteria, even if ischemia was present to the stress test or angina, and almost 20% of patients per trial were included without 
demonstrable ischemia. 
Conclusion: Clinical trials have contributed to the confusion between coronary artery disease and ischemic heart disease. This may limit the ability 
to interpret the results and apply them in practice.
